CAMBRIDGE, Mass., Feb. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of products to deliver RNAi-based treatments for devastating gastrointestinal diseases, announced that its chief executive officer, Peter Parker, will present at the Cambridge Healthech Institute's (CHI) Molecular Med Tri-Conference, as part of the Biotech Pharma Partnership Early Stage Company Showcase.
Mr. Parker will give a brief overview of Cequent, focusing on the young company's initial product pipeline, development, and commercialization strategy. His presentation is scheduled for 1:20 pm, on Tuesday, February 27, 2007, at the Moscone North Convention Center, San Francisco, California. The conference and exhibition runs through March 2, 2007.
About Cequent Pharmaceuticals, Inc.
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel products using the company's proprietary TransKingdom RNA interference (TK-RNAi) to treat and prevent genetic gastrointestinal diseases including familial polyposis, inflammatory bowel disease (Crohn's disease, ulcerative colitis, pouchitis), and colon cancer. This technique - where non- pathogenic bacteria become engines to produce and deliver RNAi - is based on ground-breaking scientific research from the Beth Israel Deaconess Medical Center/Harvard Medical School laboratory of company founder, Dr. Chiang J. Li, demonstrating TK-RNAi's powerful ability to silence specific genes and elicit promising therapeutic results. A privately held company, Cequent was established in 2006 with seed funding from Ampersand Ventures, New England Partners, and Pappas Ventures. For more information, visit http://www.cequentpharma.com.
About the Molecular Medicine Tri-conference
The 14th annual Molecular Medicine Tri-conference, produced by Cambridge Healthtech Institute, is a leading conference showcasing new technologies and therapeutic approaches for biotech and pharma. With more than 2,000 participants, it is the largest West Coast conference in the industry. For more information, visit http://www.tri-conference.com.
Media Contact: Caroline Grossman -- 781.771.5579 -- caroline.grossman@gmail.com
Cequent Pharmaceuticals, Inc.CONTACT: Caroline Grossman for Cequent Pharmaceuticals, Inc.,+1-781-771-5579, or caroline.grossman@gmail.com
